Using genetic mouse models of glioblastoma multiforme (GBM), researchers demonstrated that while the overall survival significantly increased in response to CSF-1R inhibition, tumors eventually recurred in over 50% of mice. This evidence concerns the gene CSF1R and glioblastoma.